The role of pharmacotherapy in the treatment of chronic thromboembolic pulmonary hypertension (RCD code: II-1A.5)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 2
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease caused by chronic obstruction of major pulmonary arteries. The median age of patients at diagnosis of CTEPH is 63 years and both genders are equally affected. The symptoms are usually nonspecific, particularly in the early stages of the disease, which significantly delays the diagnosis. All patients with pulmonary hypertension (PH) of the unknown aetiology should be diagnosed for CTEPH, even without the information on pulmonary embolism in the medical history. Ventilation-perfusion scintigraphy of the lungs has the highest sensitivity in the diagnosis of CTEPH. A positive result of scintigraphy suggestive of CTEPH is not enough to diagnose the disease. Right heart catheterization and angiography of the pulmonary arteries definitively confirm the diagnosis. All patients with CTEPH should receive chronic oral anticoagulation using generally vitamin K antagonists (warfarin, acenocumarol). Pulmonary endarterectomy (PEA) is the only effective treatment for eliminating the cause of the disease. However, not all patients can be referred for pulmonary endarterectomy surgery. According to data from the European CTEPH Registry of the years 2007-2009, over 40% of patients is not subjected to the operation mainly due to the distal location of thromboembolic changes. Currently, riociguat is the only approved therapeutic agent for the pharmacological treatment of inoperable/persistent CTEPH. In some cases, Off-lebel use of drugs approved for PAH may be considered in symptomatic patients with inoperable CTEPH/persistent PH after PEA. Recent advances in balloon pulmonary angioplasty make it a promising therapeutic alternative for selected patients with non-operable CTEPH. JRCD 2015; 2 (2): 4–8
Authors and Affiliations
Barbara Widlińska, Grzegorz Kopeć, Piotr Podolec
Keywords
Related Articles
- EP ID EP245454
- DOI 10.20418/jrcd.vol2no2.164
- Views 90
- Downloads 0
45‑year‑old man with hypertrophic cardiomyopathy after alcohol ablation, progression to dilated cardiomyopathy (RCD code: III‑1B.8a)
Hypertrophic cardiomyopathy (HCM) is the most common inheritable cardiac disorder with an estimated prevalence of 1:500 in the general population. In minority of patients, with the prevalence approximately of 3–5%, HCM p...
New Frontiers in Interventional Cardiology 2013 – Highlights from the biggest workshop in Central and Eastern Europe
Since 1999, at the end of each year, cardiologists, interventional cardiologists and cardiac surgeons from all over the World meet in Cracow to discuss the most challanging topics in recent cardiology. From the beginning...
Macitentan therapy for bosentan hepatic intolerance in Eisenmenger’s syndrome patient. (RCD code: II-1A.4d)
Pulmonary arterial hypertension associated with congenital heart disease is included in clinical group 1 pulmonary arterial hypertension. Eisenmenger’s syndrome develops over time as a result of large intra- and extra-ca...
The pilot study of role of electrical cardiometry in non‑invasive assessment of hemodynamic parameters in patients with pulmonary arterial hypertension (RCD code: II‑1A.1)
Background: Electrical cardiometry (EC) technique could estimate cardiac output (CO), cardiac index (CI) and other parameters related to cardiac contractility and fluid status by measuring the thoracic electrical bioimpe...
Partial recovery of left ventricular function in dilated cardiomyopathy as a result of tuberculosis treatment
We present the case of a young patient with dilated cardiomyopathy (DCM) and concomitant pulmonary tuberculosis (TB), emphasising the need for an interdisciplinary approach when considering underlying aetiology. A 36‐yea...